The patent deadlock may yet be over, as 23 members of the EU have decided to leave behind the four others and work together to create a single patent system to protect the design of products sold across their borders.
EU patent with 23 countries
Home/Policies & Legislation
|
Posted 25/02/2011
0
Post your comment

The 23 are moving forward under a rarely used provision of the Lisbon Treaty known as ‘enhanced cooperation’ and present their proposal to the EU ministers in charge of competitiveness on 14 December 2010.
The most recent plan on the table calls for an EU patent that would be translated into English as well as French or German, along with complicated provisions for manual and machine-generated translations into native languages.
However, the plans have enraged Italy, which wants an English-only patent system, and Spain, which says the plans discriminate against Spanish companies.
The other two countries objecting are the Czech Republic, which called for an impact assessment of enhanced cooperation; and Cyprus, which said it still hoped for a unanimous decision.
Europe needs to simplify the patent process in order to protect innovative products, reduce costs and create a judicial system to handle disputes. European companies spend 10 times more on patents than their American and Japanese rivals. A single patent is a critical piece of several EU strategies, including the single market, industrial policy and the ‘Innovation Union’.
The concerted action marks a victory for Belgium, which had pledged to push through a common patent before its six-month presidency ends at the end of December 2010.
Related article
Source: EurActiv
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Reports
FTC reveals extent of PBM drug mark-ups and profits
Latin American patients face 4.7-year wait for innovative treatments
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
NPRA Malaysia trials new timelines for variation applications

Home/Policies & Legislation Posted 05/11/2024
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US

Home/Policies & Legislation Posted 18/09/2024
China’s NMPA expands global ties with the Netherlands and Indonesia

Home/Policies & Legislation Posted 04/09/2024
Japan's PMDA expands influence with new office in Thailand

Home/Policies & Legislation Posted 06/08/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment